Early versus late response to PD-1-based immunotherapy in metastatic melanoma

Georg Lodde; Fang Zhao; Rudolf Herbst; Patrick Terheyden; Jochen Utikal; Claudia Pföhler; Jens Ulrich; Alexander Kreuter; Peter Möhr; Ralf Gutzmer; Friedegund Meier; Edgar Dippel; Michael Weichenthal; Philipp Jansen; Bernd Kowall; Wolfgang Galetzka; Fabian Hörst; Jens Kleesiek; Birte Hellwig; Jörg Rahnenführer; Luisa Sophie Rajcsanyi; Triinu Peters; Anke Hinney; Jan-Malte Placke; Antje Sucker; Annette Paschen; Jürgen C. Becker; Elisabeth Livingstone; Lisa Zimmer; Alpaslan Tasdogan; Alexander Roesch; Eva Hadaschik; Dirk Schadendorf; Klaus Griewank; Selma Ugurel

doi:10.1016/j.ejca.2024.114295

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Immune checkpoint inhibition (ICI) currently is the most effective treatment to induce durable responses in metastatic melanoma. The aims of this study are the characterization of patients with early, late and non-response to ICI and analysis of survival outcomes in a real-world patient cohort.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Lodde et al. (2024) studied this question.

synapsesocial.com/papers/68e5b277b6db64358754b164 https://doi.org/10.1016/j.ejca.2024.114295

View Full Paper

Ask AI

Bookmark

Share

Early versus late response to PD-1-based immunotherapy in metastatic melanoma

Ask about this paper

Abstract

Discussion

Cite This Study

Early versus late response to PD-1-based immunotherapy in metastatic melanoma

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading